Most preclinical neuroscience programs are still built around two categories of evidence. Behavior tells you what the animal does, and histology...
Histology has always carried a quiet tension. It is the most direct evidence a preclinical study can offer, a look at the actual tissue the candidate...
Remyelination has become the most interesting frontier in multiple sclerosis. The approved therapies for relapsing disease are effective at...
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its...
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug development. The clinical need is...
Toxicology is a defining step between exploratory research and clinical development. As programs move toward IND-enabling requirements, the need for...
Developing effective therapeutics for pain requires selecting endpoints that accurately reflect the biological, functional, and neurophysiological...
MD Biosciences has signed the Marseille Declaration, the first joint pharmaceutical industry statement on animal housing and use. By signing, we...
Spinal cord injury (SCI) remains one of the most challenging neurological conditions to treat, with few therapies successfully translating from the...
